Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

Cancer

Volumn 121, Issue 10, 2015, Pages 1637-1644

  Cortes, Jorge E ^a   Kantarjian, Hagop M ^a   Rea, Delphine ^b   Wetzler, Meir ^c   Lipton, Jeffrey H ^d   Akard, Luke ^e   Khoury, H Jean ^f   Michallet, Mauricette ^g   Guerci Bresler, Agnès ^h   Chuah, Charles ⁱ   Hellmann, Andrzej ^j   Digumarti, Raghunadharao ^k   Parikh, Purvish M ^l   Legros, Laurence ^m   Warzocha, Krzysztof ⁿ   Baccarani, Michele ^o   Li, Elizabeth ^p   Munteanu, Mihaela ^q   Nicolini, Franck E ^g,r  

^a UNIVERSITY OF TEXAS   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e Indiana Blood and Marrow Transplantation   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ DUKE NUS MEDICAL SCHOOL   (Singapore)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^l Indian Cooperative Oncology Network   (India)

^m CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁿ INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p PharmaStat LLC   (United States)

^q Teva Branded Pharmaceutical Products RandD   (United States)

^r INSERM   (France)

more..

Author keywords

intolerance; protein synthesis inhibitor; resistance; T315I; tyrosine kinase inhibitor (TKI)

Indexed keywords

DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA; ADULT; ANEMIA; APPLICATION SITE REACTION; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC DRUG ADMINISTRATION; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; INFECTION; INSOMNIA; LEUKOPENIA; LOBAR PNEUMONIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SKIN DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; DRUG RESISTANCE; FEMALE; LEUKEMIA, MYELOID, ACCELERATED PHASE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID, ACCELERATED PHASE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84929048341     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29240     Document Type: Article

References (28)

1. Deininger MW, Goldman JM, Melo JV,. The molecular biology of chronic myeloid leukemia. Blood. 2000; 96: 3343-3356.
2. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J,. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006; 145: 913-923.
3. Quintas-Cardama A, Cortes J,. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113: 1619-1630.
4. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012; 119: 1981-1987.
5. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367: 2075-2088.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
7. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260-2270.
8. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012; 119: 3403-3412.
9. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
10. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003; 102: 276-283.
11. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2: 117-125.
12. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12: 7374-7379.
13. Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012; 120: 2573-2580.
14. Tujebajeva RM, Graifer DM, Matasova NB, et al. Selective inhibition of the polypeptide chain elongation in eukaryotic cells. Biochim Biophys Acta. 1992; 1129: 177-182.
15. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S,. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia. 2009; 23: 1446-1454.
16. Quintas-Cardama A, Kantarjian H, Cortes J,. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009; 115: 5382-5393.
17. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J,. Altering chemosensitivity by modulating translation elongation. PLoS One. 2009; 4: e5428.
18. Wetzler M, Segal D,. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des. 2011; 17: 59-64.
19. Allan EK, Holyoake TL, Craig AR, Jorgensen HG,. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 2011; 25: 985-994.
20. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008; 112: 53-55.
21. Nicolini FE, Hayette S, Corm S, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica. 2007; 92: 1238-1241.
22. Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009; 114: 2168-2171.
23. Cortes JE, Nicolini FE, Wetzler M, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013; 13: 584-591.
24. Nicolini FE, Khoury HJ, Akard L, et al. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to 2 or more tyrosine kinase inhibitors. Haematologica. 2013; 98: e78-79.
25. Teva Pharmaceutical USA Inc. Synribo (Omacetaxine Mepesuccinate) [prescribing information]. North Wales, PA: Teva Pharmaceutical USA Inc; 2014.
26. Nicolini FE, Chomel JC, Roy L, et al. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymphoma Myeloma Leuk. 2010; 10: 394-399.
27. Coude MM, Luycx O, Cariou ME, et al. Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation. Br J Haematol. 2012; 157: 407-410.
28. Heiblig M, Sobh M, Nicolini FE,. Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives. Leuk Res. 2014; 38: 1145-1153.